Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends

Expert Review of Clinical Pharmacology

Volumn 3, Issue 3, 2010, Pages 385-396

  Wulff, Heike ^a   Castle, Neil A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Icagen Inc   (United States)

Author keywords

Asthma; Atherosclerosis; Fibrosis; ICA 17043; KCa3.1; Restenosis; Sickle cell disease; TRAM 34

Indexed keywords

11 PHENYLDIBENZAZEPINE; 4 PHENYL 4H PYRAN; 5,6 DICHLOROETHYLBENZIMIDAZOLONE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM CHANNEL L TYPE; CLOTRIMAZOLE; CYCLOHEXADIENE; CYCLOHEXADIENE LACTONE; DIPHENYLINDANONE; ETHYLBENZIMIDAZOLONE; FLINDOKALNER; NIFEDIPINE; NS 309; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KCA3.1; RILUZOLE; SENICAPOC; SKA 31; SULFONAMIDE; TRAM 34; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CHANNEL GATING; COLITIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EXERCISE INDUCED ASTHMA; HUMAN; IC 50; INFLAMMATORY DISEASE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; LUNG METASTASIS; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PLASMA HALF LIFE; PLASMA PROTEIN BINDING; POTASSIUM TRANSPORT; RESTENOSIS; RETINA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; TRAUMATIC BRAIN INJURY; UNSPECIFIED SIDE EFFECT;

EID: 77952557868     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.10.11     Document Type: Review

References (105)

1. Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LI I. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol. Rev. 57 (4), 463-472 (2005).
2. Joiner WJ, Wang LY, Tang MD, Kaczmarek LK. hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Natl Acad. Sci. USA 94 (20), 11013-11018 (1997).
3. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calciumactivated potassium channel. Proc. Natl Acad. Sci. USA 94 (21), 11651-11656 (1997).
4. Logsdon NJ, Kang J, Togo JA, Christian EP, Aiyar J. A novel gene, hKCa4, encodes the calcium-activated potassium channel in human T lymphocytes. J. Biol. Chem. 272, 32723-32726 (1997).
5. Ca 2 channels have calmodulin bound to their C-terminus.
6. KCal. J. Biol Chem. 274, 5746-5754 (1999).
7. Cheong A, Bingham AJ, Li J et al Downregulated REST transcription factor is a switch enabling critical potassium channel expression and cell proliferation. Mol. Cell 20 (1), 45-52 (2005).
8. KCal potassium channel during T-cell activation: molecular mechanism and functional consequences. J. Biol. Chem. 275, 37137-37149 (2000).
9. Gerlach AC, Gangopadhyay NN, Devor DC. Kinase-dependent regulation of the intermediate conductance, calciumdependent potassium channel, hIK1. J. Biol. Chem. 275, 585-598 (2000).
10. Ca 3.1 activity is regulated by a histidine kinase, which is a very rare form of regulation in mammals.
11. + channel KCa3.1. Proc. Natl Acad. Sci. USA 105 (38), 14442-14446 (2008).
12. K) channels occur in human enteric neurons. Auton. Neurosci. 112 (1-2), 93-97 (2004).
13. Ca channel, FIK, as a prototype for the cell growth regulatory function of the IK channel family. J. Membr. Biol. 172, 249-257 (1999).
14. + channel in vascular smooth muscle: relationship between KCa channel diversity and smooth muscle cell function. Circ. Res. 85, e33-e43 (1999).
15. Ca 3.1 constitutes a target for the prevention of restenosis.
16. + channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn-Schmiedebergs Arch. Pharmacol. 369 (6), 602-615 (2004).
17. + channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo. Arterioscler. Thromb. Vasc. Biol. 25 (4), 704-709 (2005).
18. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochem. Biophys. Acta 30, 653-654 (1958).
19. + channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J. Biol. Chem. 273 (34), 21542-21553 (1998).
20. 2+-activated potassium channel KCNN4. J. Biol. Chem. 279 (46), 47681-47687 (2004).
21. + channels in human erythrocyte apoptosis. Am. J. Physiol. Cell. Physiol. 285 (6), C1553-C1560 (2003).
22. Elliott JI, Higgins CF. IKCa1 activity is required for cell shrinkage, phosphatidylserine translocation and death in T lymphocyte apoptosis. EMBO Rep. 4 (2), 189-194 (2003).
23. Taylor SR, Gonzalez-Begne M, Dewhurst S et al. Sequential shrinkage and swelling underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and death. J. Immunol. 180 (1), 300-308 (2008).
24. Ca3.1) in the inner mitochondrial membrane of human colon cancer cells. Cell Calcium 45 (5), 509-516 (2009).
25. + channels are required for human lung mast cell migration. Thorax 61 (10), 880-885 (2006).
26. Pena TL, Chen SH, Konieczny SF, Rane SG. Ras/MEK/ERK up-regulation of the fibroblast KCa channel FIK is a common mechanism for basic fibroblast growth factor and transforming growth factor-β suppression of myogenesis. J. Biol. Chem. 275 (18), 13677-13682 (2000).
27. + channel expression during B-cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 173, 776-786 (2004).
28. Chung I, Zelivyanskaya M, Gendelman HE. Mononuclear phagocyte biophysiology influences brain transendothelial and tissue migration: implication for HIV-1- associated dementia. J. Neuroimmunol. 122 (1-2), 40-54 (2002).
29. + channels for lysophosphatidic acid-induced microglia migration. Eur. J. Neurosci. 19, 1469-1474 (2004).
30. Tharp DL, Casati J, Turk JR, Bowles DK. Functional upregulation of intermediate conductance calcium activated potassium channels is necessary for coronary smooth muscle cell dedifferentiation and migration. FASEB J. 19, A1628 (2005).
31. KCal) mediates phenotypic modulation of coronary smooth muscle. Am. J. Physiol. Heart Circ. Physiol. 291 (5), H2493-H2503 (2006).
32. + channels and the microglial respiratory burst. Am. J. Physiol. Cell. Physiol. 280 (4), C796-C806 (2001).
33. Ca3.1 contributes to microglia activation and nitric oxidedependent neurodegeneration. J. Neurosci. 27 (1), 234-244 (2007).
34. Wolfs JL, Wielders SJ, Comfurius P et al. Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood 108 (7), 2223-2228 (2006).
35. Rufo PA, Jiang L, Moe SJ, Brugnara C, Alper SL, Lencer WI. The antifungal antibiotic, clotriamzole, inhibits Clsecretion by polarized monolayers of human colonic epithelial cells. J. Clin. Invest. 98, 2066-2075 (1996).
36. + channel. Am. J. Physiol. 271 (5 Pt 1), L775-L784 (1996).
37. Devor DC, Singh AK, Lambert LC, DeLuca A, Frizzel RA, Bridges RJ. Bicarbonate and chloride secretion in Calu-3 human airway epithelia cells. J. Gen. Physiol. 113, 743-760 (1999).
38. + channel (rSK4) of colonic crypts. Pflugers Arch. 438 (4), 437-444 (1999).
39. +-channels suppresses EDHF-mediated vasodilation. Br. J. Pharmacol. 138 (4), 594-601 (2003).
40. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23 (8), 374-380 (2002).
41. + channels in normal and impaired EDHF-dilator responses - relevance to cardiovascular pathologies and drug discovery. Br. J. Pharmacol. 157 (4), 509-526 (2009).
42. Ca 3.1 play a critical role in mediating the endothelium-derived hyperpolarizing factor response.
43. + channel. Circ. Res. 99 (5), 537-544 (2006).
44. Ca 3.1 channels during endotheliumderived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ. Res. 102 (10), 1247-1255 (2008).
45. Ledoux J, Taylor MS, Bonev AD et al Functional architecture of inositol 1, 4, 5-trisphosphate signaling in restricted spaces of myoendothelial projections. Proc. Natl Acad. Sci. USA 105 (28), 9627-9632 (2008).
46. Ca 3.1) in mice causes subtle erythrocyte macrocytosis and progressive splenomegaly. Pflugers Arch. 458 (2), 291-302 (2009).
47. Ca 3.1 might be a target for increasing insulin secretion.
48. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calciumactivated potassium channels and their therapeutic indications. Curr. Med. Chem. 14 (13), 1437-1457 (2007).
49. + channels. Eur. J. Biochem. 242 (3), 491-498 (1996).
50. 2+-activated potassium channel. Mol. Pharmacol. 63, 409-418 (2003).
51. + channels. J. Biol. Chem. 275, 1201-1208 (2000).
52. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267 (17), 11789-11793 (1992).
53. + channel: the imidazole ring is not required for inhibitory activity J. Pharmacol. Exp. Ther. 273, 266-272 (1995).
54. + transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J. Clin. Invest. 93, 1670-1676 (1994).
55. Ca 3.1 blockade with clotrimazole reduces erythrocyte dehydration in patients with sickle cell anemia.
56. Suzuki S, Kurata N, Nishimura Y, Yasuhara H, Satoh T Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. Eur. J. Drug Metab. Pharmacokinet. 25 (2), 121-126 (2000).
57. Luo G, Cunningham M, Kim S et al CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30 (7), 795-804 (2002).
58. KCal: a potential immunosuppressant. Proc. Natl Acad. Sci. USA 97, 8151-8156 (2000).
59. KCal,. J. Biol. Chem. 276, 32040-32045 (2001).
60. McNaughton-Smith GA, Burns JF, Stocker J W et al. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J. Med. Chem. 51 (4), 976-982 (2008).
61. Ataga KI, Orringer EP, Styles L et al Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 26 (11), 1557-1564 (2006).
62. Abbassi M, Shresta S, Raman G et al. Formulation-based approach to support early drug discovery and development efforts: a case study for entereric microencapsulation of a novel immunosuppressant TRAM-34. J. Microencapsulation (2009) (In press).
63. K (Ca) channel blockers. Bioorg Med. Chem. Lett. 13 (16), 2637-2639 (2003).
64. KCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg. Med. Chem. Lett. 15 (2), 401-404 (2005).
65. Ca 3.1 blocker has beneficial effects in traumatic brain injury.
66. 2+-dependent. Biochim. Biophys. Acta 1420 (1-2), 231-240 (1999).
67. + channels. Am. J. Physiol Cell. Physiol. 278 (3), C570-C581 (2000).
68. + channels. J. Biol. Chem. 276 (13), 9762-9769 (2001).
69. Singh S, Syme CA, Singh AK, Devor DC, Bridges RJ. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 296 (2), 600-611 (2001).
70. + channels by NS309 (6, 7-dichloro-1 H-indole-2, 3-dione 3-oxime). Biochim. Biophys. Acta 1665 (1-2), 1-5 (2004).
71. Ca 3.1 potassium channels, potentiates the endothelium-derived hyper polarizing factor response and lowers blood pressure. Mol. Pharmacol. 75 (2), 281-295 (2009).
72. + channels in urinary bladder smooth muscle cells. J. Pharmacol. Sci. 100 (3), 237-241 (2006).
73. Chou CC, Lunn CA, Murgolo NJ. KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev. Mol. Diagn. 8 (2), 179-187 (2008).
74. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J. Clin. Invest. 92, 520-526 (1993).
75. ® is effective in an animal model of sickle cell disease.
76. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111, 1703-1713 (2003).
77. Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. Potassium channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 25, 280-289 (2004).
78. Reich EP, Cui L, Yang L et al. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. Eur. J. Immunol 35 (4), 1027-1036 (2005).
79. Chou CC. Blocking ion channel KCNN4 alleviates inflammation symptoms by arresting the synthesis of key proinflammatory factors. In: IBC Assays and Cellular Targets. CA, USA (2005).
80. Wojtulewski JA, Gow PJ, Walter J et al Clotrimazole in rheumatoid arthritis. Ann. Rheum. Dis. 39, 469-472 (1980).
81. v 1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant. Proc. 41 (6), 2601-2606 (2009).
82. Ca 3.1 might constitute a therapeutic target for inflammatory bowel disease.
83. KCal in human mast cells. FASEB J. 19 (8), 1006-1008 (2005).
84. V1.3 as novel targets for asthma therapy. Br. J. Pharmacol. 157 (8), 1330-1339 (2009).
85. ® in a sheep model of asthma.
86. Ca 3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic podulation and limits stenosis. Arterioscler. Thromb. Vasc. Biol. 28, 1084-1089 (2008).
87. Ca 3.1 might constitute a target for atherosclerosis.
88. Ca 3.1 prevent kidney fibrosis.
89. Benzaquen LR, Brugnara C, Byers HR, Gattoni-Celli S, Halperin JA. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med. 1, 534-540 (1995).
90. + channels inhibits progression of human endometrial cancer. Oncogene 26 (35), 5107-5114 (2007).
91. Ca 3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 74 (6), 740-749 (2008).
92. + channel KCNN4. J. Physiol. (Lond.) 583 (Pt 2), 705-717 (2007).
93. + conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J. Clin. Invest. 100 (12), 3111-3120 (1997).
94. ® (ICA-17043): a potential therapy for the prevention and treatment of hemolysisassociated complications in sickle cell anemia. Expert Opin. Invest. Drugs 18 (2), 231-239 (2009). •• Review summarizing the safety, pharmacokinetics and Phase II trial results for Senicapoc.
95. ® (ICA-17043), in patients with sickle cell anemia. Blood 111 (8), 3991-3997 (2008).
96. Swerdlow P, Ataga KI, Smith W, Saunthararajah Y, Stocker JW A 48-week open-label study of Sincapoc (ICA-17042), a Gardos channel blocker, in patients with sickle cell disease. Blood 108, (2006) (Abstract 685).
97. Gribkoff VK, Starrett JE, Dworetzky SI et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 7, 471-477 (2001).
98. Jensen BS. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev. 8 (4), 353-360 (2002).
99. + cells in ischemic brain lesions. J. Neuroimmunol. 126 (1-2), 107-115 (2002).
100. President and Fellows of Harvard College; Children Medical Center Corporation; Ion Pharmaceuticals. Inc., WO9734589 (1997).
101. President and Fellows of Harvard College; Children Medical Center Corporation; NuChem Pharmaceuticals Inc., US6992079 (2006).
102. President and Fellows of Harvard College; Children Medical Center Corporation; NuChem Pharmaceuticals Inc., US7342038 (2008).
103. Icagen Inc., US7119112 (2006).
104. Bayer A G, Germany, DE-9619612645 (1997).
105. Icagen company press release. 26 October 2009 www.icagen. com